TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05273359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: 15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Benralizumab placebo
Description: 15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison (control) group; no intervention
Description: 15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
Study: NCT05893927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes education web site application
Description: The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
Study: NCT04747340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness Resilience and Action (TARA)
Description: See arm-description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: See arm-description
Study: NCT05839977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual telerehabilitation
Description: The exercise will consist of strength and balance exercises using the Homebalance ® system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises based on videos
Description: intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
Study: NCT05956743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progressive relaxation exercise sessions
Description: Intervention Group: A total of 6 weeks of planning will be made with the working group.~1. week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2. ,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 1. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained.
Study: NCT04908501

Intervention type: OTHER
Intervention: Intervention
Description: The program intervention has three focuses : the prioritization of appropriateness indicators, the automation and visualization of the prioritized indicators, and support for practice analysis groups (PAG) based on e-feedback from automated indicators
Study: NCT06099275

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Cardiac output measured by transthoracic echocardiography (TTE)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Cardiac output measured by transthoracic echocardiography (TTE)
Study: NCT06034184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
Study: NCT05927974

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive testing
Description: Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.

Intervention type: DIAGNOSTIC_TEST
Intervention: Active testing
Description: Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications.
Study: NCT04197219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV day 1 of each cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg PO BID continuously
Study: NCT05434780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology taping
Description: Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
Study: NCT05463848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Pill taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Pill taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pill taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pill taken by mouth
Study: NCT05231213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
Study: NCT05123924

Intervention type: OTHER
Intervention: Evaluation of respiratory capacity, respiratory muscle strength and fatigue
Description: The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time.

Intervention type: OTHER
Intervention: Evaluation of respiratory capacity, respiratory muscle strength and fatigue
Description: The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time.
Study: NCT06492993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The CHN meets with DDBHH participant over sessions to provide navigation support through the cancer screening process.
Study: NCT05231213

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
Study: NCT05404100

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: SAVR or TAVR
Study: NCT06252480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 4 variance of different intensities of tDCS (0.5mA, 1 mA, 1.5mA and 2mA). At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment.
Study: NCT05299749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stg-rt-fMRI-Neurofeeback
Description: the patients will receive real-time feedback from the brain activity of the superior temporal gyrus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-rt-fMRI-Neurofeedback
Description: the patients will receive real-time feedback from the brain activity of the somato-motor cortex
Study: NCT04716296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be given for the second stage of the DBS surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be given for the second stage of the DBS surgery.
Study: NCT05296109

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)
Description: The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
Study: NCT04629066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Cardiac Rehabilitation (CR)
Description: Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR.
Study: NCT00538811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alpha-2b, ribavirin, interferon-gamma,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha-2b, ribavirin, amantadine
Study: NCT04838080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine
Description: Two applications on Days 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine
Description: Two applications on Days 0 and 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two applications on Days 0 and 21
Study: NCT05453383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib;Toripalimab
Description: Anlotinib Hydrochloride;Toripalimab injiection
Study: NCT05448638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the combination of transversus thoracic muscle plane and pectoral nerves blocks
Description: For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the pectoral nerves block only
Description: For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
Study: NCT05338424

Intervention type: OTHER
Intervention: Sprint Interval Training (SIT)
Description: Active arm-- exercise dictated by protocol
Study: NCT04783558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-based NAS Caregiving Tool
Description: The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
Study: NCT06087055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/Ritonavir
Description: Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally once daily for 9 days from Days 8 through 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/Ritonavir
Description: Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
Study: NCT05862662

Intervention type: OTHER
Intervention: MOVE Program
Description: Mobility Opportunities Via Education functional therapy program.

Intervention type: OTHER
Intervention: MOVE Program
Description: Mobility Opportunities Via Education functional therapy program.
Study: NCT05681143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Prevention Arm
Description: The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
Study: NCT05138952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: 30-day mediation program comprising:~1. Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~2. 10-minutes of daily mindfulness meditation practice with the Headspace Inc app.
Study: NCT05561556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: One 20mg capsule daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: One 20mg capsule daily for 8 weeks
Study: NCT03647891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
Study: NCT06208943

Intervention type: OTHER
Intervention: cross-sectional MRI and EEG assessments (NO INTERVENTION)
Description: n/a there is no intervention in this observational study

Intervention type: OTHER
Intervention: cross-sectional MRI and EEG assessments (NO INTERVENTION)
Description: n/a there is no intervention in this observational study
Study: NCT06335004

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Patients will undergo a magnetic resonance imaging for clinical purposes to which additional sequences. Post gadolinium research sequences will be acquired only if intravenous gadolinium needs to be administered for clinical purposes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Patients will undergo a magnetic resonance imaging for clinical purposes to which additional sequences. Post gadolinium research sequences will be acquired only if intravenous gadolinium needs to be administered for clinical purposes.
Study: NCT05089786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Neuro Type 1.0 System with Echo Focusing
Description: MR-Guided Focused Ultrasound
Study: NCT05488496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature-based social intervention (NBSI)
Description: The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + menu with nature-based activities
Description: Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
Study: NCT06523101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJ009
Description: Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.